Recently, it was suggested that ADAM28 might play a role in key immunomodulatory mechanisms since CD20+/CD22+/ADAM28+ B cells were shown to promote response to immune checkpoint inhibitor therapy in non-small-cell lung cancer (41). Here, CD22 is linked to non-small cell lung carcinoma.